These findings suggest that Notch3 is a potential marker of FLSPCs and regulates the differentiation of FLSPCs into hepatocytes; thus, Notch3 might deserve attention as a possible target driving the use of FLSPCs in the treatment of ESLD (end-stage liver disease). The gene discussed is NOTCH3; the disease is chronic liver failure.